Unknown

Dataset Information

0

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib.


ABSTRACT: INTRODUCTION:This comprehensive observational study aimed to gain insight into adherence to nilotinib and the effect of (non)adherence on exposure (Cmin) and treatment outcomes. METHODS:Chronic myeloid leukemia (CML) patients using nilotinib were followed for 12 months. Adherence was measured by Medication Event Monitoring System (MEMS), pill count, and Medication Adherence Report Scale (MARS-5). Nilotinib Cmin and patient-reported outcomes (i.e., quality of life, side effects, beliefs, satisfaction) were measured at baseline, 3, 6, and 12 months. RESULTS:Sixty-eight patients (57.5 ± 15.0 years, 49% female) participated. Median adherence to nilotinib (MEMS and pill count) was ? 99% and adherence < 90% was rare. Self-reported nonadherence (MARS-5) increased in the first year of treatment to a third of patients. In line with the strong beliefs in the necessity of taking nilotinib, forgetting to take a dose was more prevalent than intentionally adjusting/skipping doses. Nilotinib Cmin were generally above the therapeutic target in 95% of patients. Patients reported a variety of side effects, of which fatigue was most frequent. The mean Cmin was higher in patients who reported severe itching and fatigue. The overall 1-year MMR rate ranged from 47 to 71%. CONCLUSION:Substantial nonadherence (< 90%) to nilotinib was rare and nilotinib Cmin were generally above the therapeutic target. Lack of response in our group of patients was not related to nonadherence or inadequate Cmin. Nevertheless, a considerable number of patients experienced difficulties in adhering to the twice daily fasted dosing regimen, emphasizing the importance of continuous support of medication adherence in CML. CLINICAL TRIAL REGISTRATION:NTR3992 (Netherlands Trial Register, www.trialregister.nl ).

SUBMITTER: Boons CCLM 

PROVIDER: S-EPMC7419465 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib.

Boons Christel C L M CCLM   Timmers Lonneke L   Janssen Jeroen J W M JJWM   Westerweel Peter E PE   Blijlevens Nicole M A NMA   Smit Willem M WM   Bartelink Imke H IH   Wilschut Janneke A JA   Swart Eleonora L EL   Hendrikse N Harry NH   Hugtenburg Jacqueline G JG  

European journal of clinical pharmacology 20200602 9


<h4>Introduction</h4>This comprehensive observational study aimed to gain insight into adherence to nilotinib and the effect of (non)adherence on exposure (C<sub>min</sub>) and treatment outcomes.<h4>Methods</h4>Chronic myeloid leukemia (CML) patients using nilotinib were followed for 12 months. Adherence was measured by Medication Event Monitoring System (MEMS), pill count, and Medication Adherence Report Scale (MARS-5). Nilotinib C<sub>min</sub> and patient-reported outcomes (i.e., quality of  ...[more]

Similar Datasets

| S-EPMC8393793 | biostudies-literature
| S-EPMC6439982 | biostudies-literature
| S-EPMC6777037 | biostudies-literature
| S-EPMC5030243 | biostudies-literature